Literature DB >> 11465803

Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency.

S Nathanson1, V Frémeaux-Bacchi, G Deschênes.   

Abstract

A patient with homozygous factor H deficiency presented with hemolytic uremic syndrome (HUS) at the age of 7 months. After a 2-year period of stability, renal failure and erythrocyte fragmentation recurred between the age of 3 and 4 years. Fresh frozen plasma infusions allowed renal function to be improved and erythrocyte fragmentation to be stopped. Withdrawal of plasma therapy led to a relapse of the biological signs of HUS.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11465803     DOI： 10.1007/s004670100609

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  19 in total

1.  A favorable outcome of hemolytic uremic syndrome with factor H deficiency.

Authors:  Z Birsin Ozçakar; Fatoş Yalçinkaya; Emel Derelli; Banu Acar; Selçuk Yüksel; Ozden Tulunay; Mesiha Ekim
Journal:  Pediatr Nephrol       Date:  2004-05-11       Impact factor: 3.714

2.  Thrombotic microangiopathy: what not to learn from a meta-analysis.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

Review 3.  Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013.

Authors:  Caitlin E Carter; Nadine M Benador
Journal:  Pediatr Nephrol       Date:  2013-06-29       Impact factor: 3.714

4.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

Authors:  Gema Ariceta; Nesrin Besbas; Sally Johnson; Diana Karpman; Daniel Landau; Christoph Licht; Chantal Loirat; Carmine Pecoraro; C Mark Taylor; Nicole Van de Kar; Johan Vandewalle; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

5.  Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.

Authors:  Fadi Fakhouri; Elena Goicoechea de Jorge; Frédérique Brune; Philippe Azam; H Terence Cook; Matthew C Pickering
Journal:  Kidney Int       Date:  2010-05-05       Impact factor: 10.612

6.  Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation.

Authors:  Samhar I Al-Akash; P Stephen Almond; Van H Savell; Salam I Gharaybeh; Cris Hogue
Journal:  Pediatr Nephrol       Date:  2010-12-02       Impact factor: 3.714

Review 7.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

8.  Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality.

Authors:  Angela Gerber; Antje H Kirchhoff-Moradpour; Silke Obieglo; Matthias Brandis; Michael Kirschfink; Peter F Zipfel; Judith A Goodship; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2003-06-26       Impact factor: 3.714

Review 9.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

10.  Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase.

Authors:  Danielle Paixão-Cavalcante; Steven Hanson; Marina Botto; H Terence Cook; Matthew C Pickering
Journal:  Mol Immunol       Date:  2009-05-02       Impact factor: 4.407
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.